Burgdorf – Ypsomed (SIX: YPSN) and CamDiab announce their agreement to integrate mylife Loop automated insulin delivery (AID) system with Abbott’s next-generation dual glucose-ketone sensor, which is currently under development.
The planned integration will enhance the capabilities of mylife Loop by enabling people real-time access to both glucose and ketone data through a single wearable sensor. This enhanced functionality is designed to support more informed diabetes management, particularly for people with type 1 diabetes who are at risk of diabetic ketoacidosis (DKA), a serious complication caused by elevated ketone levels in the absence of sufficient insulin.
mylife Loop combines the adaptive mylife CamAPS FX app, the mylife YpsoPump insulin pump and a continuous glucose monitoring (CGM) sensor to create an interoperable AID solution designed to simplify diabetes management.
By integrating Abbott’s future dual glucose-ketone sensor into mylife Loop, we aim to offer people with diabetes greater safety and confidence in their daily therapy,
said Sébastien Delarive, Chief Business Officer Diabetes Care at Ypsomed.
We are excited to collaborate with Abbott on this important innovation. By incorporating future ketone monitoring alongside glucose data with the mylife CamAPS FX app, we are taking a major step forward in delivering a closed-loop solution that is designed to enhance safety and reduces burden for people – and their loved ones living with type 1 diabetes,
said Prof. Roman Hovorka, Director of CamDiab Ltd.
Subject to regulatory approval, the integrated solution is expected to become available in selected markets following the commercial release of Abbott’s dual glucose-ketone sensor, which is under development today.
About mylife Loop
mylife Loop is a modular AID solution for the treatment of type 1 diabetes. The adaptive mylife CamAPS FX algorithm runs on the personal smartphone and is approved for people with type 1 diabetes aged one year and older*, depending on the sensor used for continuous glucose monitoring. It is the only algorithm indicated for pregnant women with type 1 diabetes*. mylife Loop integrates the mylife YpsoPump insulin pump and a compatible sensor for continuous glucose monitoring, including FreeStyle Libre 3 or FreeStyle Libre 3 Plus from Abbott or Dexcom G6 from Dexcom. mylife Loop is marketed in most European countries, Canada, Australia and New Zealand. Further information and details can be found at www.mylife-diabetes-care.com/loop.
CamDiab Ltd
CamDiab Ltd is a digital health and personalized medicine company focused on the design, development, and commercialization of its world leading, interoperable CamAPS FX hybrid closed loop app. The CamAPS FX algorithm is designed to be adaptive and self-learning, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. For further information, visit www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter@CamAPS_FX.
Susanne Köhler
*Depending on local indication.
mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries. // CamAPS is a registered trademark of CamDiab Ltd. // Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries // FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission // iPhone is trademark of Apple Inc., registered in the US and other countries and regions. // Other trademarks are the property of their respective owners.
